CAN10

CAN10

The first Phase 1 clinical trial was initiated in September 2023 and investigates how different doses of CAN10 are tolerated, absorbed, and how long CAN10 remains in the body.

In the first part of the study, CAN10 was administered as a single dose intravenously to healthy subjects. In the second part of the study, CAN10 is given as repeated subcutaneous doses to either healthy subjects or participants with mild to moderate plaque psoriasis. The evaluation of both single dose and repeated dosing in healthy subjects has been completed and deemed safe. For the participants with psoriasis, the evaluation is ongoing. Details of the clinical study can be found here.

Results from the first CAN10 PK model with data from repeated SC dosing indicated a high bioavailability of CAN10 and confirm dosing selection every 4 weeks for Phase 2 studies. In addition, CAN10 demonstrates potent and long-lasting inhibitory effects on several key inflammatory biomarkers, further strengthening the potential benefit of CAN10 in inflammatory diseases

Otsuka Pharmaceutical Co., Ltd. has acquired the anti-IL1RAP antibody program CAN10 from Cantargia and will complete the ongoing Phase I study.